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Abstract 
Human cutaneous melanoma is an aggressive and chemotherapy resistant 
type of cancer. Although the development of new targeted therapies and 
immunologic agents has completely changed the treatment guidelines, one 
of the most important tasks for the future will be to overcome acquired 
resistance. In this thesis we investigated different pharmacological 
strategies against human melanoma cells. Particularly, we demonstrated the 
theranostic properties (i.e., the ability of imaging and pharmacological 
silencing activity) of a molecular beacon-oligodeoxynucleotide (MB) that 
targets survivin mRNA. This may represent an innovative approach for 
cancer diagnosis and treatment in melanoma patients because survivin is an 
inhibitor of apoptosis overexpressed in tumor cells and almost undetectable 
in human melanocytes. We also provide evidence of the pro-apoptotic 
effect and cell cycle arrest ability of AM251, a cannabinoid type 1 receptor 
antagonist/inverse agonist with an anticancer potency comparable to that 
observed for cisplatin. This compound may be a potential prototype for the 
development of promising diarylpyrazole derivatives to be evaluated in 
human cutaneous melanoma. Finally, we demonstrated that the 
cannabinoid type 1 receptor is markedly expressed in stem-like cells and 
not expressed in the BRAF-wild type parental cells. Otherwise, both 
primary BRAF-mutated melanoma cultures and their correspondent 
melanoma-initiating cells expressed high levels of this receptor subtype. 
These findings suggest a possible role of the endocannabinoid system in 
determining the phenotype of melanoma cells and their potential to cause 
central nervous system metastases. 
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Sommario 
Il melanoma è un tumore aggressivo e resistente alla chemioterapia. Lo 
sviluppo di nuove terapie mirate e immunoterapie ha completamente 
cambiato le linee guida del trattamento del melanoma ma, il compito più 
importante per il futuro è quello di superare la resistenza. In questa tesi 
abbiamo studiato diverse strategie farmacologiche contro le cellule di 
melanoma umano. In particolare, abbiamo dimostrato le proprietà 
teranostiche (cioè, capacità di imaging coniugata con attività farmacologica 
di silenziamento) di un oligodesossinucleotide antisenso molecular beacon 
(MB) diretto verso l’mRNA codificante per la survivina. Questo può 
rappresentare un approccio innovativo per la diagnosi ed il trattamento in 
pazienti affetti da melanoma perché la survivina è un inibitore dell’apoptosi 
sovraespresso in diversi tipi di tumore e non rilevabile nella maggior parte 
dei tessuti sani (melanociti). Abbiamo anche valutato le capacità di blocco 
del ciclo cellulare e pro-apoptotica di AM251, un antagonista/agonista 
inverso del recettore dei cannabinoidi di tipo 1 (CB1) con una potenza 
antitumorale paragonabile a quella osservata per il cisplatino. Questo 
composto può pertanto rappresentare un potenziale prototipo per lo 
sviluppo di derivati diaril-pirazolici con attività nel melanoma cutaneo 
umano. Infine, abbiamo dimostrato la marcata espressione del recettore 
CB1 in cellule simil-staminali derivanti da pazienti e la sua non espressione 
nelle cellule parentali tipo BRAF non mutato. Invece, le culture primarie di 
melanoma con mutazione BRAF e le cellule simil-staminali derivanti 
esprimono alti livelli di questo sottotipo recettoriale. Questi risultati 
suggeriscono un possibile ruolo del sistema endocannabinoide sia nel 
determinare il fenotipo di melanoma sia nel causare metastasi a livello del 
sistema nervoso centrale. 
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Chapter 1 
Introduction 
1.1 Definition of melanoma 
Melanoma is a form of cancer that begins in melanocytes, cells that make 
the pigment melanin (Fig. 1.1). It may begin in a mole (skin melanoma), 
but can also begin in other pigmented tissues, such as in the eye or in the 
intestines (National Cancer Institute, Melanoma, 2014). It is called also 
malignant melanoma, melanocarcinoma, melanoepithelioma, 
melanosarcoma (Merriam-Webster, 2014). 
 
Figure 1.1  Schematic representation of normal skin. The pullout shows a 
close-up of the squamous cell and basal cell layers of the epidermis, the basement 
membrane in between the epidermis and dermis, and the dermis with blood 
vessels. Melanin is shown in the cell (National Cancer Institute, Melanoma 
Anatomy, 2014). 
1.2 Epidemiology 
Until a few years ago, melanoma was considered a tumor rare, and very 
rare until adolescence, while currently it represents an incidence in 
continued growth (Tsao et al., 2004) and the second most common cancer 
in adolescents (Kauffmann et al., 2014).  
2 
It is estimated that in the last decade, melanoma skin has reached the 
132,000 new cases a year worldwide: an increase of about 15% compared 
to the previous decade (Tsao et al., 2004). Its incidence varies considerably 
between different areas of the world. Melanoma affects predominantly 
caucasians, but there are significant geographical differences: the highest 
rates are observed in populations of  Australia and New Zealand, which 
have values 2-3 times higher than  North America and Europe. In Europe 
there is a gradual reduction from north to south. Incidence rates are low  in 
Asian and black people (Globacan 2012, 2014). About 80% of cutaneous 
melanomas that arise annually in the world affects the populations of North 
America, Europe and Oceania (Fig. 1.2) (Globacan 2012, 2014). The 
current melanoma risk for Australian and New Zealander populations may 
be as high as 1 out of 50 (Rigel, 2010). 
Figure 1.2 Estimated number of cancer cases (x1000) of melanoma of skin in 
all ages and both sexes (Globacan 2012, 2014). 
In 2014, an estimated, 76,100 patients will be diagnosed and about 9700 
patients will die of melanoma in the United States (Siegel et al., 2014). In 
Italy, an estimated 11,000 new cases in 2014 (with a slight predominance 
in males) (Aiom-airtum, 2014). Melanoma is increasing in men more 
rapidly than any other malignancy except lung cancer (Fig. 1.3) (Jemal et 
al., 2011). Although melanoma can affect persons of essentially any age, it 
is mainly a disease of adulthood, with median ages of diagnosis and death 
between 61 and 68 years, respectively (Weinstock, 2012). 
3 
Figure 1.3 Incidence and mortality of melanoma worldwide in all ages 
(Globacan 2012, 2014). 
The 5-year survival rate for localized (stage I and II) melanoma is 98%; 
however, this drops to 16% in cases where cancer has metastasized to 
distant sites or organs (Wolchok, 2014). 
1.3 Risk Factors 
The risk of developing melanoma is highly dependent on the interaction 
between endogenous risk factors and environmental risk factors. The 
recognition of groups of individuals with different risk and the application 
of appropriate strategies for prevention, are the key points to reduce 
morbidity and mortality from melanoma (Tsao et al., 2004). The skin 
phototype, the total number of nevi and in particular of dysplastic nevi, 
indices of solar exposure, the family history of melanoma which has been 
cited for the hereditary mutation of the tumor suppressor gene CDKN2A 
(cyclin-dependent kinase inhibitor type 2A) (Aitken et al., 1999) and a long 
series of genetic alterations (Gudbjartsson et al., 2008) as well as the states 
of immunodeficiency are personal risk factors. These factors (Tab. 1.1) 
4 
contribute independently in the development of cutaneous melanoma 
(Gandini  et al., 2005).  
 
Table 1.1 Risk factors for melanoma (Helfand et al., 2001). 
Exposure to UV rays, which generally gives double the risk of developing 
melanoma in exposed with respect to non-exposed individuals, increases 
markedly in phototype clear people (Vainio et al., 2000). Moreover, it was 
shown that advanced age and male sex are associated with a higher 
incidence and a poorer prognosis (Fig. 1.3) (Lasithiotakis et al., 2008). 
Retrospective studies on a large scale have shown that a previous 
melanoma is the most important predictor for a subsequent melanoma. It 
was also calculated that the cumulative probability of developing a second 
melanoma at 5 and 10 years of distance is 2.8% and 3.6%, respectively 
(Goggins et al., 2003). 
Several molecular genetic studies have shown the relevant role of some 
genes as risk factors for susceptibility to melanoma (Fig. 1.6). To date, two 
high penetrance susceptibility genes, the CDKN2A and CDK4 (cyclin-
dependent kinase type 4), and a low-penetrance susceptibility gene, the 
MC1R (melanocortin 1 receptor) have been identified (Fargnoli et al., 
2006; Meyle et al., 2009).  
1.4 Melanoma pathogenesis 
Melanoma is characterized by complex changes in multiple signaling 
pathways that control cell proliferation and ability to evade the cell death 
processes. Impairment or hyper-activation of some components of these 
5 
pathways may lead to malignant transformation and cancer development. 
The most relevant signaling pathways involved in development and 
progression of melanoma are Rb/E2F, MAPK/ERK, PI3K/Akt/, NF-kB, 
Wnt/β-catenin, Notch, Jak/STAT, cyclin/CDK, JNK/c-Jun/AP-1, MITF 
and some growth factors. 
In the following sub-paragraphs further insights on the principal pathways 
are given for their relevance in the comprehension of the action mechanism 
of drugs cited in the 1.6 paragraph. 
1.4.1 Rb/E2F 
E2F is a transcription factor involved in the cell cycle regulation and 
synthesis of DNA in eukaryotic cells through binding site in the target 
promoter sequence (Halaban et al., 2005). G1/S transition is controlled by 
transcription factor E2F, which triggers expression of target genes that 
encode proteins involved in DNA synthesis and its regulation (Uzdensky et 
al., 2013). Rb (retinoblastoma) is a tumor suppressor that represses the 
expression of E2F regulated genes required for cell cycle progression. Rb is 
inactivated in melanomas and other cancer cells by phosphorylation 
catalyzed by persistent cyclin dependent kinase (CDK) activity (Fig.1.4). 
Figure 1.4 Pathway Rb/E2F (Hardin et al. 2012). 
The molecular events that lead to autonomous proliferation of melanoma 
cells include sustained activity of CDK2 (cyclin dependent kinase type 2), 
CDK4 and CDK6 (cyclin dependent kinase type 6) as a result of mutations 
or loss of CDK inhibitors such as p16
INK4
 (cyclin-dependent kinase 
inhibitor 2A) and p27
KIP1
 (cyclin-dependent kinase inhibitor 1B) (Fig. 1.5).  
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Figure 1.5 Schematic representation of the eukaryotic cell cycle with cyclins  
playing a role in the different stages (Currais et al., 2009). 
In melanoma cells Rb is permanently and highly phosphorylated (Carnero, 
2002). This prevents their binding to E2F and so E2F result activated and 
mantains the transcription of target genes involved in G1/S transition, that 
is a key event in malignant melanocyte transformation (Ibrahim et al., 
2009). 
1.4.2 CDKN2A  
The gene CDKN2A simultaneously encodes two tumor suppressor 
proteins, p16
INK4a
 and p14
ARF
 (ARF tumor suppressor) (Fig. 1.5). In 
pathogenesis of both sporadic and familial melanoma CDKN2A is often 
inactivated due to deletion, mutation or promoter hypermethylation. 
CDKN2A is the principal target in UV mediated melanoma (Harland et al., 
2014). Its mutations were found in 20-40% of familial cutaneous 
melanomas (Fig.1.6). 
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Figure 1.6 Prevalence of CDKN2A mutations in hereditary melanoma 
(Harland et al., 2014). 
Protein p16
INK4a
 prevents interaction of CDK4/6 with cyclin D1(Fig. 1.5) 
that leads to decrease in pRb phosphorylation, sequestration of E2F, and 
G1/S arrest (Fig. 1.4). The mutations levels are low in normal proliferating 
cells but rapidly increases under stressful genotoxic impacts such as UV 
(Giles et al., 2012). These alterations correspond to melanoma progression 
and poor prognosis. 
Protein p14
ARF
 boosts p53-mediated apoptosis and thereby prevents 
reproduction of tumor cells. Inactivation of p53 is the most common 
molecular injury in human cancer cells. However, in melanoma the TP53 
gene that encodes p53 mutates rather seldom (only 9%) (Mihic et al., 
2010). 
1.4.3 MAPK/ERK  
MAPK (mitogen-activated protein kinase)/ERK (extracellular signal-
regulated kinases) pathway is also known as Ras-Raf-MEK-ERK pathway 
from the proteins involved. Constitutive activation of the this pathway 
mediates critical events in melanoma growth, progression, regulation of 
apoptosis, adhesion, migration, and melanoma vascularization (Eisenmann 
et al., 2003; Woods et al., 2001). 
Ras identifies a class of proteins called small GTPases, located at the 
plasma membrane which are involved in cellular signal transduction, 
whereas the downstream kinases Raf, MEK and ERK are cytosolic 
residents (Fig. 1.7). 
After binding of some ligands, such as growth factors to their respective 
receptor (tyrosine kinase, RTK), receptor dimerization triggers the intrinsic 
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tyrosine-kinase, activating MAPK pathway. Like other GTPase proteins, 
Ras cycles between the GDP (guanosine diphosphate) -bound inactive form 
and the GTP (guanosine -5'triphosphate) -bound active form. In the 
quiescent state, Ras exists in the GDP-bound form. The binding of SOS 
(Son Of Sevenless, a small GTPase) to Ras causes a change in the Ras 
conformation and leads to the dissociation of GDP and binding of GTP. 
GTP-bound Ras is the activator of this signaling module. It initiates the 
signal cascade by phosphorylating Raf. Raf, in turn, phosphorylates the 
MEK (MEK1 and MEK2), which then phosphorylates ERK (extracellular 
signal-regulated kinases, ERK1 and ERK2). Activated ERKs then 
translocate into the nucleus where they phosphorylate specific substrates 
that are involved in the regulation of various cellular responses (Chin, 
2003) ERK induced production of various transcription factors involved in 
regulation of proliferation and apoptosis prevention and G1/S transition as 
cyclin D (Fig. 1.6) (Uzdensky et al., 2013).  
 
Figure 1.7 Activation of the MAPK/ERK signaling pathway (Chin, 2003). 
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Mutated Ras or Raf proteins permanently stimulate cell proliferation, tumor 
invasion and metastasis. Such mutations were observed in >90% of clinical 
cases of melanoma (Smalley, 2010).  
The Ras subfamily consists of three isoforms: H-Ras, K-Ras and N-Ras. 
NRAS is mainly related to melanoma pathogenesis. NRAS mutations were 
found in 15-30% of melanoma cases (Sekulic et al., 2008). 
The Raf subfamily consists of isoforms A-Raf, B-Raf and C-Raf (also 
called Raf-1). Braf mutations are the most relevant in melanoma and have 
been found in 60-70% of primary melanoma but also in a high % of 
cutaneous melanocyte nevi; it is considered a risk factor involved in 
initiation rather than in progression of melanomas. Although more than 40 
different mutations in BRAF gene have been described, the most clinically 
relevant mutation is the BRAF T1799A, which results in the substitution of 
valine by glutamic acid (V600E) in the kinase domain of the protein. 
Mutated Braf protein permanently activates ERK and stimulates 
proliferation. The mutation V600E, is found in 80-90% of all BRAF 
mutations in melanoma. ARAF and CRAF are found seldom in melanoma 
and actually are not considered relevant (Platz et al., 2008). 
1.4.4 PI3K/Akt/mTOR 
The phosphatidylinositol-3-kinase (PI3K)/ protein kinase B (Akt) and the 
mammalian target of rapamycin (mTOR) signaling pathways (Fig. 1.8) 
make a crucial network to many aspects of cell growth and survival, in 
physiological as well as in pathological conditions (e.g., cancer) (Porta et 
al., 2014).
 
The PI3K/Akt pathway is a key regulator of survival during cellular stress 
(Datta et al., 1999). Since tumors exist in an intrinsically stressful 
environment (characterized by limited nutrient and oxygen supply, as well 
as by low pH), the role of this pathway in cancer appears to be crucial. 
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Figure 1.8 Schematic of signaling through the PI3K/AKT pathway 
(Hennessy et al., 2005). 
PI3Ks constitute a lipid kinase family enzymes capable of phosphorylating 
the 3 position hydroxyl group of the inositol ring of phosphatidylinositol. 
The PI3K/AKT and related pathways are important in internalizing the 
effects of external growth factors and of membrane tyrosine kinases. 
Activation of growth factor receptor protein tyrosine kinases results in 
autophosphorylation on tyrosine residues (Fig. 1.8) and subsequent events 
to activate these intracellular pathways. This leads to activation of PI3K 
and this leads to the production of the second messenger 
phosphatidylinositol-3,4,5-triphosphate (PIP3) from the substrate 
phosphatidylinositol-4,4-bisphosphate (PIP2). This provides anchoring of 
Akt at the plasma membrane, where it is phosphorylated by 
phosphoinositide dependent protein kinase-1 (PDK1) that is also activated 
by PI3K. 
Activation of Akt regulates several cell processes involved in cell survival 
and cell cycle progression. Akt phosphorylates and thereby inactivates the 
pro-apoptotic proteins Bad (Bcl-2-associated death promoter), Bim, Bax 
(Bcl-2-associated X protein) and caspase-9. Moreover, Akt- activates the 
protein MDM2 (Mouse double minute 2), which down-regulates p53 
(tumor suppressor). Akt also activates the transcription factors CREB 
(cAMP response element-binding protein), E2F and NF-κB (Nuclear factor 
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kappa-light-chain-enhancer of activated B cells) involved in cell protection 
and survival. Activated Akt stimulates proliferation and tumorigenesis 
through up-regulation of cyclin D1, which controls G1/S transition, and 
inhibition of p21 (cyclin-dependent kinase inhibitor 1) and p27, which 
prevent G1/S transition (Fig. 1.5). Akt-mediated activation of mTOR also 
suppresses apoptosis and stimulates protein synthesis, proliferation and 
angiogenesis. Other effects of PI3K/Akt/mTOR is mediated by the 
transcription factor HIF1 (hypoxia-inducible factor-1) and VEGF (vascular 
endothelial growth factor) (Madhunapantula et al, 2009). 
The Akt family comprises three isoforms: Akt1, Akt 2 and Akt3, but only 
Akt3 is the predominant isoform in melanoma cells. Overexpression and 
overactivation of Akt3 are characteristic for 60-70% of sporadic 
melanomas. Significant phosphorylation of Akt3 was registered in 17%, 
43%, 49% and 77% of biopsies from normal nevi, dysplastic nevi, primary 
melanoma and melanoma metastases, respectively (Stahl et al., 2004). 
The PI3K/Akt pathway is regulated by the lipid phosphatase PTEN, 
(phosphatase and tensin homolog) that acts as a tumor suppressor by 
inhibiting cell growth and enhancing cellular sensitivity to apoptosis. 
PTEN removes phosphate groups from PIP3 and converts it into PIP2 (Fig. 
1.8), preventing Akt binding and  activation. PTEN also inhibits the 
Raf/ERK pathway (Stahl et al., 2003) and its impairment has been found 
related to about 40-50% cases of sporadic melanoma (Stahl et al., 2003). 
Sun ultraviolet radiation, the major risk factor for skin cancer, induces 
PTEN mutations that promote melanoma promotes melanoma growth 
(Hocker et al., 2007). The PTEN and NRAS or BRAF mutations cooperate 
in melanoma development and metastasis (Dankort et al., 2009). 
mTOR is a bioenergetic sensor and it is a master regulator of protein 
synthesis, proliferation, autophagy, apoptosis and other cellular processes. 
It serves as a sensor of abundance of metabolites and energy depletion in 
the cell (Fig. 1.8). It is stimulated by protein Rag, which is activated by free 
amino acids. AMP-activated protein kinase (AMPK) inhibits mTOR and 
thereby mTOR-mediated protein synthesis, when ATP (adenosine 
triphosphate) depletion induces accumulation of AMP (adenosine 
monophosphate). Activation of the PI3K/Akt pathway by growth factors 
stimulates mTOR (Fig. 1.9). mTOR forms two signaling complexes: 
mTORC1 and mTORC2. mTORC1 contains proteins mTOR, GβL (G 
protein β-like) and RAPTOR (regulatory-associated protein of mTOR), 
whereas in mTOR2 RAPTOR is substituted by RICTOR (rapamycin-
insensitive companion of mammalian target of rapamycin). mTORC1 
stimulates protein synthesis and inhibits autophagy. mTORC2 regulates 
remodeling of the actin cytoskeleton and the cell shape. It also activates 
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Akt thereby creating the regulatory feedback, which results in Akt-
mediated inhibition of the pro-apoptotic protein GSK3 (glycogen synthase 
kinase 3), and stimulates proliferation through activation of cyclin D1 and 
inhibition of p27. The activity of Akt and cell survival depends on the fine 
balance between mTORC1 and mTORC2 activities because the two 
different mTORC complexes have opposite effects on Akt signaling, with 
mTORC1 suppressing Akt signaling and mTORC2 directly activating Akt 
through a phosphorylation event at Ser473 (Sarbassov et al., 2004; 
Uzdensky et al., 2013). 
 
Figure 1.9 mTOR signaling pathways (Guertin, 2009). 
mTOR involvement in melanoma development has been suggested since it 
is activated in 73% of malignant melanomas versus 4% in benign nevi 
(Karbowniczek et al., 2008). Activation of the mTOR pathway in 
cutaneous melanoma is associated with poor prognosis (Populo et al., 
2011). Activation of mTOR in response to growth, nutrient and energy 
signals leads to an increase in protein synthesis, which is required for 
tumor development (Dancey, 2010).  
1.4.5 NF-kB 
NF-κB is a transcriptional factor consisting of two subunits: p50 and 
RelA/p65 (Fig. 1.10). In the cytoplasm, NF-kB forms the inactive complex 
with the inhibitory protein IkB (nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor) that prevents its translocation into the 
nucleus. In response to external factors or under stress conditions, different 
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signaling proteins such as Akt, ERK, p38 (mitogen-activated protein 
kinases) and NIK (NF-kappa-B-inducing kinase) phosphorylate IkB kinase 
(IKK, inhibitor of nuclear factor kappa-B kinase) that induces detachment 
and proteasomal degradation of IkB. Free NF-kB (p50/p65), which may be 
additionally phosphorylated/activated by a variety of other enzymes, is 
transferred into the nucleus, where it initiates transcription of more than 
150 target genes involved in regulation of apoptosis, proliferation, 
inflammation, immune reactions, metastasis and tumor angiogenesis 
(Uzdensky et al., 2013; Madonna et al., 2012). Constitutive activation of 
Akt3 in melanoma leads to up-regulation of NF-kB and contributes to 
tumor progression. Akt3 phosphorylates and activates NF-kB either 
directly or through phosphorylation of IKKα. This is followed by IKKα-
mediated phosphorylation of p65 that stimulates nuclear localization and 
DNA-binding of NF-kB (Amiri et al., 2005). 
 
 
Figure 1.10 The NF-kB-related signaling pathway (Uzdensky et al., 2013). 
Up-regulation and constitutive activation of various components of the NF-
kB pathway have been found related to progression and metastasis of 
melanoma. The NF-kB-mediated expression of anti-apoptotic proteins such 
as IAP (Inhibitor of apoptosis), survivin, TRAF1/2 (tumor necrosis factor 
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receptor associated factor 1/2), and Bcl-2 (B-cell lymphoma 2) family 
members increases along with melanoma progression to invasive and 
metastatic phases. NF-kB also controls the expression of cyclin D1 and 
CDK2 that regulate proliferation. Overexpression of these proteins allows 
melanoma cells to escape the cell-cycle control and initiate tumor growth. 
The activation of NF-kB in melanoma cells is associated with deregulation 
of upstream signaling pathways,  such as Ras/Raf/MAPK, PI3K/Akt, and 
TRAF/NIK/NF-κB. In melanoma tumorigenesis and progression, in 
addition to the role played by specific melanoma cell pathways, as above 
reported, there are other features which must be considered, i.e. the 
relevance of  stem cells and the role played by the immune system. 
1.4.6 Melanoma stem cells 
Cancer stem cells (CSC) are the subset of cells found in a malignancy that 
is responsible not only for the formation of tumors, but also for their 
inexorable progression. These primitive melanoma cells (Fig. 1.11) are not 
only capable of self-renewal (produce new stem cells), reprogramming and 
phenotype-switching capability but also it gives rise to a diversity of cells 
that differentiate and after a finite number of divisions, eventually succumb 
to programmed cell death (differentiation plasticity). Cancer stem cells may 
also confer virulence via immune evasion and multidrug resistance, and 
potentially via vasculogenic mimicry and transition to migratory and 
metastasizing derivatives (Girouard et al., 2011). 
 
Figure 1.11 Malignant melanoma-initiating cells (MMICs) (Lee et al., 2014). 
The presence of a minor subpopulation of CSC is observed in the 
melanoma tissue and drives tumor initiation and progression. 
Chemotherapy and/or radiotherapy of a tumor kills a bulk of rapidly 
proliferating cancer cells but not quiescent CSC that are more resistant and 
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can survive and reinitiate tumor growth (Schatton et al., 2008). Melanoma 
biopsies contain from 1 to 20% of melanoma stem cells (Na et al., 2009; 
Schatton et al., 2008). Quintana and collaborators (2008) have shown that 1 
in 4 melanoma cells can initiate a new tumor in immune-deficient animals, 
i.e. up to 25% melanoma cells are potentially tumorigenic. 
The future development of the anti-melanoma therapy will involve the  
searches of specific markers of melanoma-initiating cells different from 
markers of normal stem cells. 
1.4.7 Melanoma immune escape 
The immune system’s natural capacity to detect and destroy abnormal cells 
may prevent the development of many cancers. However, some cancers, as 
melanoma, are able to avoid detection and destruction by the immune 
system. The hypothesis is that tumor variants become more resistant to 
identification and/or elimination by the immune system with a consequent  
tumor growth. This process has been called “cancer immunoediting”. This 
hypothesis explains the observation that tumors often become clinically 
evident years after their molecular origin. At the end of this equilibrium 
between the immune system and tumor growth, the immune response 
allows for the outgrowth of a subpopulation of tumor cells (Herrera-
Gonzalez, 2013). For deepening also Gajewski et al., 2013. 
1.5 Cancer staging 
Staging is based on detailed information regarding the histologic subtype, 
Clark level, Breslow depth, dermal mitotic rate per square millimeter, 
degree of atypia, presence of lymphocytic invasion, presence of ulceration 
or tumor regression, presence of lymphovascular or perineural invasion, 
microsatellitosis, and margin assessment (Fig. 1.12) (Kauffmann et al., 
2014). 
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Figure 1.12 Overview of cancer staging (NCCN Guidelines–Melanoma, 
1.2015).  
Staging of melanoma is based on the 2010 American Joint Committee on 
Cancer (AJCC) seventh edition TNM (Tumor-Node-Metastasis) system 
(AJCC, Cancer staging, 2014) (Tab. 1.2). 
 
Table 1.2 AJCC, seventh edition, staging criteria for cutaneous (Kauffmann 
et al., 2014). 
The T category is based on the thickness of the melanoma, mitotic rate and 
ulcerations seen in the biopsy. N stands for spread to nearby lymph nodes. 
The M indicates distant metastasis. The presence of tumor in the lymph 
nodes is a key prognostic indicator, and accurate identification is 
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paramount for both accurate staging and decision-making on further 
therapy.  
Understanding the cancer’s stage is also critical to identifying clinical trials 
that may be appropriate for particular patients (AJCC, Cancer staging, 
2014).  
1.6 Treatment 
Surgical excision is the primary treatment for melanoma (Dummer et al., 
2012). The surgical treatment of melanoma may be completed by the 
enlargement of the excision, based on the thickness of the histological 
lesion. Sentinel lymph node biopsy (SLNB) is a minimally invasive staging 
procedure developed to identify patients with subclinical nodal metastases 
at higher risk of recurrence, who could be candidates for complete lymph 
node dissection or adjuvant systemic therapy (NCCN Guidelines–
Melanoma, 1.2015). In Fig. 1.13  the recommendations of National 
Comprehensive Cancer Network (NCCN) 1-2015 that put in relationship 
clinical stage, primary treatment and adjuvant treatment, are reported. 
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Figure 1.13 Guidelines for treatment of melanoma (NCCN 1-2015). 
As regards melanoma pharmacological therapy, it is radically changed  
after key molecular and immunological insights over the past decade. 
Whereas 5 years ago, treatment for advanced melanoma was restricted to 
the alkylating agent dacarbazine and the immunostimulants interleukin-2 
(IL-2) and interferon-α 2b (INF-α2b), today the therapeutic menu includes 
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precise therapies (Fig. 1.14) that target key determinants in oncogenic 
pathways and immune checkpoints (Miller et al., 2014). 
Figure 1.14 Timeline of FDA-approved medications for melanoma (Miller et 
al., 2014). 
1.6.1 Chemotherapy 
Chemotherapy with cytotoxic agents has been used for the treatment of 
metastatic melanoma for over three decades. Among the antitumoral 
agents, efficacy is modest in metastatic melanoma including alkylating 
agents (dacarbazine, temozolomide, nitrosoureas), analogues of platinum 
(cisplatin, carboplatin) and microtubular toxins (vincas and taxanes), which 
have been used alone or in combination (Bhatia et al., 2009). Specifically 
in relation to cytotoxic chemotherapy, dacarbazine used as a 
chemotherapeutic agent still represents the single most common option. It 
was demonstrated that combinations of cytotoxic agents can produce low 
response rates, although higher than monotherapy with dacarbazine, which 
are associated with increased toxicity and do not extend significantly the 
survival of patients (Bhatia et al., 2009). 
1.6.2  Immunotherapy 
Melanoma is characterized as one of the most immunogenic tumors 
because of the presence of tumor-infiltrating lymphocytes in resected 
melanoma, occasional spontaneous regression, and clinical responses to 
immune stimulation (Mouawad et al., 2010). For these reason, melanoma 
has long been considered a promising target for immunotherapeutic 
approaches.  In 1998, the FDA (US Food and Drug Administration) 
approved the use of the immune molecule IL-2 to treat advanced melanoma 
(Fig. 1.14). This provided the first proof-of-principle that an immune-based 
treatment could provide durable control of the disease. The immune 
molecule IFNα has also been used alone after surgery or in combination 
with other agents to treat advanced melanoma (Wolchok, 2014). 
Furthermore, the immunogenicity of melanoma has led investigators to 
study novel immune strategies for overcoming immune system evasion by 
tumors (Mouawad et al., 2010).  
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A promising avenue of clinical research in melanoma is the use of immune 
checkpoint inhibitors. By blocking inhibitory molecules or, alternatively, 
activating stimulatory molecules, these treatments are designed to unleash 
or enhance pre-existing anti-cancer immune responses. Several checkpoint 
inhibitors, targeting multiple different checkpoints, are currently in 
development (Wolchok et al., 2014). T cells self-regulate their activation 
through CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) expression. CTLA-
4 functions as a negative co-stimulatory molecule for the T cell; therefore, 
therapies that antagonize CTLA-4 remove the brakes from T cells leading 
to a net effect of T cell hyper-responsiveness (Melero et al., 2007). Several 
human monoclonal antibodies, i.e. ipilimumab (Yervoy®, MDX-010; 
Bristol-Myers Squibb, Medarex, Princeton, NJ), tremelimumab (CP-
675,206; Pfizer Pharmaceuticals, New York), and others. These antibodies 
have been demonstrated to induce tumor regression and may prolong time 
to disease progression free and are in clinical development. 
Ipilimumab (Fig. 1.15) is a fully human monoclonal IgG1κ antibody 
against CTLA-4, an immune inhibitory molecule expressed in activated T 
cells and suppressor T regulatory cells. Activation of the cellular immune 
response involves the interaction of T cell receptors with major 
histocompatibility complex molecules on antigen-presenting cells (APCs). 
This requires costimulation where ligand B7 on APC binds to CD28 
(Cluster of Differentiation 28) on T cells, which triggers T cell 
proliferation. A negative co-stimulation signal is transduced by CTLA-4, 
which is present in T cells, and interaction of CTLA-4 with the same B7 
ligand inhibits T cell activation and proliferation (Chambers et al., 2001; 
(Melero et al., 2007; Garber, 2010). 
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Figure 1.15  Ipilimumab stimulates antitumor immunity by blocking CTLA4, 
a natural brake on T cells, and allowing their unimpeded 'costimulation' (Garber, 
2010). 
Ipilimumab was approved by the FDA in February 2011 (Fig. 1.14) and by 
the European Medicines Agency in July 2011 for use in the treatment of 
advanced malignant melanoma in patients not responding to chemotherapy, 
with or without previous exposure to immunotherapy (Hanaizi et al., 2012); 
moreover,multiple clinical trials using this drug for the treatment of other 
malignancies are ongoing. 
In 2011, the immunotherapy Ipilimumab (Yervoy®) became the first drug 
ever shown to extend survival for patients with metastatic melanoma. 
Results from a large, phase III trial of Ipilimumab demonstrated that it 
reduced the risk of death by 32% and nearly doubled the patients surviving 
to 1 and 2 years, with some patients experiencing complete and durable 
clinical regressions lasting for years (Wolchok, 2014). Ipilimumab induces 
a significant increase in the frequency of circulating regulatory T cells 
(Tregs) and increase in the induction of tumor infiltrating Tregs at 6 weeks 
(Tarhini et al., 2012). Ipilimumab is the first agent that has been 
demonstrated to improve overall survival (OS) in patients with metastatic 
melanoma, which has a very poor prognosis, in randomized phase III 
clinical trials (Graziani et al., 2012). 
Tremelimumab is a fully human IgG2 antibody, which is directed against 
human CTLA-4, as ipilimumab. Tremelimumab did not produce a 
statistically significant advantage in overall survival compared to first-line 
standard-of-care chemotherapy in a phase III randomized trial reported in 
the Journal of Clinical Oncology in patients with advanced melanoma 
(Ribas et al, 2013). 
Urelumab is a humanized agonistic monoclonal antibody targeting the 
CD137 receptor with potential immunostimulatory and antineoplastic 
activities. CD137 is a member of the tumor necrosis factor receptor 
(TNFR) family and functions as a costimulatory molecule. Urelumab 
specifically binds to and activates CD137-expressing immune cells, 
stimulating an immune response, in particular a cytotoxic T cell response 
against tumor cells (Molckovsky et al., 2008).  
Pembrolizumab is a humanized monoclonal IgG4 antibody directed against 
human cell surface receptor PD-1 (programmed death-1 or programmed 
cell death-1) with immune-potentiating activity. Upon administration, 
pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed 
on the surface of activated T cells, and blocks the binding of PD-1 by its 
ligands, which results in the activation of T-cell-mediated immune 
responses against tumor cells (Fig. 1.16). The ligands for PD-1 include PD-
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L1 (programmed death-ligand 1), which is expressed on APCs and 
overexpressed on certain cancer cells, and PD-L2 (programmed death-
ligand 2), which is primarily expressed on APCs. Activated PD-1 
negatively regulates T-cell activation through the suppression of the 
PI3K/Akt pathway (Fig. 1.9). 
 
Figure 1.16 PD-1 checkpoints (Brahmer et al., 2010). 
In July 2014, Bristol-Myers Squibb anti-PD-1 antibody, Nivolumab 
received its first regulatory approval for use in inoperable melanoma in 
Japan, under the name Opdivo, making it the first anti-PD-1 cancer 
therapy. 
In September 2014, Merck's anti-PD-1 antibody, Keytruda 
(pembrolizumab, MK-3475), was FDA approved for the treatment of 
advanced or unresectable melanoma (Fig. 1.14) in patients failing prior 
treatment with ipilimumab and/or , if they have a BRAF V600E mutation, a 
BRAF or MEK inhibitor (Wolchok, 2014). 
There are also other anti-PD1 antibody under investigation: 1) MEDI4736, 
an anti-PD-L1 antibody made by MedImmune/AstraZeneca, is being tested 
in a phase I/II trial for melanoma and 2) MPDL3280A, an anti-PD-L1 
antibody developed by Roche/Genentech, that is being tested in a phase I 
trial in melanoma as well as numerous other cancers (Wolchok, 2014). 
Since melanoma is well known to be an immunogenic tumor, there have 
been many efforts to develop vaccines that induce an anti-melanoma 
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response (Ozao-Choy et al., 2014). Vaccine strategies are highly varied and 
options vary from the simplest peptide vaccines to the most complex 
autologous whole-tumor cells. 
After several decades of failed attempts at developing potent therapeutic 
cancer vaccines, the first  was approved in prostate cancer by FDA in 2010 
Sipuleucel-T (Provenge, Dendreon Corporation). A trial of gp100:209-
217(210M) peptide vaccination in melanoma showed a response rate 
higher and progression-free survival longer with vaccine and IL-2 than 
with IL-2 alone. Nevertheless, additional work is required to optimize 
vaccine strategies using peptides (Schwartzentruber et al., 2011). 
1.6.3  Targeted Therapy 
The main characteristics of targeted antineoplastic treatment is that the 
drugs act specifically on their intended target which have specific effects 
on the tumor (Martí et al., 2012). The number of possible therapeutic 
targets in melanoma is increasing with an improvement in our 
understanding of the biology of melanoma. 
c-KIT inhibitors 
c-KIT(tyrosine-protein kinase or CD117) is a growth factor receptor in 
epidermal melanocytes and has an essential role in the differentiation and 
migration of melanocytic cells during embryonic development. The ligand 
for KIT (tyrosine-protein kinase) is stem cell factor (SCF) and binding of 
SCF to c-KIT induces the activation of downstream signaling pathways 
that mediate growth and survival signals within the cell, including the 
PI3K-Akt-mTOR  (Fig. 1.9) and Ras-Raf-MEK-ERK (Fig. 1.8) pathways.  
C-KIT is mutated in approximately 20% of sun-induced skin damage. For 
these reasons, c-KIT has been considered a potential therapeutic target in 
melanoma and two c-KIT inhibitors, i.e., imatinib (Gleevec, Novartis 
Pharmaceuticals Corporation) and dasatinib (Bristol-Myers Squibb), are 
under evaluation for treating melanoma. Imatinib (Gleevec) have shown 
promise in improving clinical outcomes in patients with advanced 
melanoma (Miller et al., 2014). 
Braf/ERK inhibitors 
One of the most common signaling pathways affected by mutations in 
melanoma is the Braf/ERK pathway (paragraph 1.4.3 of the present 
manuscript) (Fig. 1.8). The V600E mutation, which comprises nearly 90% 
of the observed mutations in Braf obviates the need for activation by Ras 
and results in constitutive activation and unregulated phosphorylation of 
downstream effectors such as MEK (Cantwell-Dorris et al., 2011). As 
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shown in Table 1.3, six BRAF inhibitors are under evaluation for 
melanoma.  
 
Table 1.3 Clinical trials of Braf/MEK inhibitors for treating melanoma 
(Tseng et al, 2013). 
Vemurafenib was launched in 2011 in the US after FDA approval for 
BRAF V600E mutation positive unresectable or metastatic melanoma and 
in the UK after EMA (European Medicine Agency) approval in 2012 (Fig. 
1.14). 
In a phase III randomized controlled trial of patients with metastatic 
melanoma and BRAF mutation, vemurafenib significantly reduced the 
risks of death and disease progression by 63% and 74%, respectively, 
compared with dacarbazine (Fig. 1.17). The response rate in patients who 
received vemurafenib was 48.4%, which was almost 9 times higher than 
that in patients who received chemotherapy (5.5%). Furthermore, 84% of 
the patients who received vemurafenib were alive after 6 months compared 
with 64% who received chemotherapy: the median over survival with 
vemurafenib (10.5 months) was longer than that with dacarbazine 
(Chapman et al., 2011). 
Figure 1.17 Progression-free survival from a trial comparing vemurafenib 
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with dacarbazine in patients with BRAFV600E-mutated melanoma (Chapman et 
al.,2011). 
Despite this initial success, numerous challenges remain with selective Braf 
inibithors. For example, only half of melanomas possess activating 
mutations in BRAF gene. In addition, the duration of response to Braf-
inhibitor is relatively short secondary to acquired and adaptive resistance. 
Lastly, selective Braf inhibition has been associated with rare, but serious, 
adverse effects such as the rise of secondary malignancies (Sullivan et al., 
2013). 
Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an 
inhibition of growth factor-mediated cell signaling and cellular 
proliferation. Trametinib was found to improve progression free survival 
compared to dacarbazine (4.8 months vs 1.5 months) in a phase III trial 
suggesting that MEK could be a valid therapeutic target in BRAF-mutant 
melanoma. There were no reports of cutaneous squamous cell carcinoma or 
hyperproliferative skin lesions, such as those seen with the Braf inhibitors. 
Based on the clinical benefit of the MEK-inhibitor, the FDA (Fig. 1.14) 
approved trametinib (Mekinist) in May of 2013 (Miller et al., 2014). 
The resistance to Braf-inhibitors is associated with reactivation of the 
MAPK pathway; so future strategies will include rationally designed, triple 
and quadruple therapeutic regimens targeting complementary oncogenic 
pathways. Additional targets include PI3K, mTOR, MDM2, BCL-2, PDGF 
(platelet-derived growth factor), HSP90 (Heat-shock protein 90), IGF 
(insulin-like growth factor), MITF (microphthalmia-associated 
transcription factor), Notch and several other cyclin-dependent kinases 
(Miller et al., 2014). 
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Chapter 2 
Experimental Section: Theranostic 
properties of a survivin-directed 
molecular beacon in human 
melanoma cells 
2.1 Introduction 
Survivin is a member of the inhibitor of apoptosis family (Ambrosini  et 
al., 1997) that plays a key role in the regulation of cell division, apoptosis, 
cell migration and metastasis (Altieri, 2008; Groner et al., 2014; Mita et al., 
2008). Furthermore, survivin is involved in the promotion of angiogenesis 
and chemoresistance (Mita et al., 2008). Unlike other anti-apoptotic 
proteins, survivin is undetectable in most terminally differentiated normal 
tissues, while it is overexpressed in human cancer (Altieri, 2001). For 
instance, survivin is highly overexpressed in malignant melanoma cells 
compared with normal melanocytic nevi and normal differentiated skin 
tissues (Grossman et al., 1999). Furthermore, a retrospective analysis 
performed in melanoma patients has revealed that survivin up-regulation is 
correlated with decreased survival rate, increased relapse, and 
chemoresistance occurrence (Hartman et al., 2013; Takeuchi et al., 2005; 
Chen et al., 2009). These features make survivin a promising target against 
which novel anti-cancer drugs could be developed. 
Pharmacological modulation of survivin was tagged with its evolving 
functional complexity associated with various cell-signaling cascades 
including PI3K/AKT, mTOR, ERK, MAPK, signal transducer and 
activator of transcription (STAT), hypoxia-inducible factor-1α, HSP90, 
p53, Bcl2, epidermal growth factor receptor (EGFR), VEGF etc (Kanwar et 
al., 2013). It is widely recognised that therapeutic strategies targeting 
surviving or surviving expression (e.g., antisense oligonucleotides and 
short interfering RNA, siRNA) can induce tumor cell death, circumvent 
drug resistance and sensitize cancer cells to chemotherapeutic drugs (Mita 
et al., 2008). 
More recently, much attention has been directed to molecular beacons 
(MBs) as potential theranostic agents (Wang et al., 2013). MBs are stem-
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loop-folded oligodeoxyribonucleotides with fluorophore and quencher dyes 
conjugated to the opposite ends of the hairpin (Fig. 2.1).  
 
Figure 2.1 Molecular beacon structure and mechanism of action. 
In the absence of the complementary nucleic acid target (mRNA, in the 
case of this work), the fluorescence of the fluorophore is quenched by the 
closely located quencher (Kolpashchikov et al., 2012). Otherwise, the 
hybridization with target nucleic acid opens the hairpin, generates probe-
analyte duplex that physically separates the fluorophore from quencher, 
allowing a fluorescence signal to be emitted upon excitation (Santangelo et 
al., 2006; Giannetti et al., 2013). 
It has been reported that MB technology may allow assessing gene 
expression in vivo with high sensitivity and low background signal and 
may help to noninvasively detect cancer in its early stages. Furthermore, 
MB can also produce therapeutic effect by binding and down-regulating its 
target gene (Han et al., 2013). Several lines of evidence provided by the 
antisense therapy research, demonstrate that complementary pairing of a 
short segment of an exogenous oligonucleotide to mRNA can have a 
profound impact on protein expression levels and even cell fate. In fact, 
binding of MB to mRNA can trigger RNase H mediated mRNA 
degradation (Santangelo et al., 2006).  
In the current study, we provide evidence of the simultaneous imaging and 
pro-apoptotic activities of a previously described MB (Nitin et al., 2004) 
and demonstrate that such effects are associated with selective targeting of 
survivin mRNA in human melanoma cells. This approach may represent an 
innovative strategy for the development of novel theranostic drugs in 
human cancer. 
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2.2 Materials and Methods 
2.2.1 Cell cultures 
The human malignant melanoma A375 cell line (American Type Culture 
Collection, Rockville, MD, USA) was cultured at 37°C in a humidified 
atmosphere containing 5% CO2 in DMEM (Dulbecco's modified Eagle's 
medium) supplemented with l-glutamine (2 mM), 10% heat-inactivated 
fetal bovine serum (FBS) and 1% (w/v) penicillin/streptomycin (Sigma-
Aldrich, Milan, Italy). The human metastatic melanoma 501 Mel cell line 
was a kind gift from Dr. Poliseno (Oncogenomics Unit, Core Research 
Laboratory, Istituto Toscano Tumori c/o IFC-CNR, Pisa, Italy). 501 Mel 
cells were cultured in the same condition of A375 with glucose 
supplement. Human bronchial smooth muscle cells (BSMC; Lonza, 
Walkersville, MD, USA) were maintained exactly as recommended by the 
manufacturer in an optimized medium containing 5% fetal bovine serum, 
5.5 mM glucose, 50 μg/ml gentamicin, 50 ng/ml amphotericin-B, 5 ng/ml 
insulin, 2 ng/ml basic fibroblast growth factor and 0.5 ng/ml epidermal 
growth factor (SmGM-2 Bullet Kit, Lonza). Human melanocytes 
(PromoCell GmbH, Germany) were cultured at 37°C in a humidified 
atmosphere containing 5% CO2 in Melanocyte Growth Medium M2 
(PromoCell GmbH, Germany). Human monocytes were a kind gift from 
Dr. Celi (Department of Surgery, Medical, Molecular, and Critical Area 
Pathology). Monocyte isolation was performed as described previously 
(Neri et al., 2012). The procedure was approved by the local ethics 
committee at the University of Pisa and was in accordance with the 
Declaration of Helsinki. A signed consent was obtained from all donors.  
2.2.2 Drugs 
Docetaxel (DTX) and Cisplatin (CisPt) were purchased from Sigma–
Aldrich, Milan, Italy. DTX was dissolved in dimethyl sulfoxide (DMSO) 
and diluted with culture medium (DMSO final concentration of 0.0001%, 
v/v), while CisPt was dissolved in water.  
2.2.3 Transfection  
Cells were transfected with 100 nM antisense oligodeoxynucleotides using 
Lipofectamine 2000 (Ref. 11668-027, Invitrogen Life Technologies, 
Carlsbad, CA, USA), which has been reported to yield high transfection 
efficiency (≈70%) in A375 cells (Zhou et al., 2013). A molecular beacon 
(MB), which targets nucleotides 149–163 of survivin mRNA, and the other 
oligodeoxynucleotides were synthesized by IBA (Göttingen, Germany) 
(Nitin et al., 2004). ATTO647N (λabs 644 nm, λem 669 nm) and Blackberry 
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Quencher 650 (λmax~650 nm, useful absorbance between 550 and 750 nm) 
were used as fluorophore/quencher pair. A fluorescent DNA probe, with 
the same oligonucleotide sequence of MB but not structured as a molecular 
beacon and labelled only with the ATTO647N dye, was used as control. 
Oligonucleotide sequences are listed in Table 2.1. 
 
Table 2.1 Oligonucleotide sequences of Molecular Beacon (MB) and probe. 
2.2.4 In vitro confocal microscopy in living cells 
Laser scanning confocal microscopy was carried out by using a microscope 
RadiacePLUS (Bio-Rad). Briefly, cells were plated on 35 mm µ-dishes 
(Ibidi Giemme Snc, Milan, Italy) and treated with 100 nM antisense 
oligodeoxynucleotides (MB or probe). All observations were done with an 
oil immersion x 40 Nikon objective lens (Numerical aperture NA=1.3). 
Fluorescence was evaluated at different time points during the transfection 
(excitation and emission wavelengths of 644 and 669 nm, respectively). 
Acquired images were processed using the open source Image-J software. 
2.2.5 RT-PCR and quantitative real-time PCR analyses 
Total RNA from cells was extracted by using the RNeasy
®
 Mini kit, 
following manufacturer’s instructions, and reverse-transcribed by the 
QuantiTect
®
 Reverse Transcription kit (Qiagen, Valencia, CA, USA). RT-
PCRs (Reverse transcriptase polymerase chain reaction) were performed by 
the HotStartTaq Master Mix kit (Qiagen, Valencia, CA, USA). Primer 
sequences are listed in Table 2. Thermal cycle conditions were as follows: 
95°C for 15 min, 35 cycles of denaturation at 95°C for 1 min followed by 
annealing and extension at 72°C for 1 and 10 min, respectively. Detection 
of the RT-PCR products was performed by agarose gel electrophoresis and 
ethidium bromide staining.  
Real-time PCR (polymerase chain reaction) was performed with SsoFast 
Eva Green Supermix (Ref. 172-5201, Bio-Rad, CA, USA). Samples were 
amplified using the following thermal profile: 95°C for 30 s, 40 cycles of 
denaturation at 95°C 15 s followed by annealing for 30 s and 72°C for 30 s, 
with a final step at 65°C for 5 s. GAPDH (glyceraldehyde 3-phosphate 
dehydrogenase ) and β-actin were used as housekeeping genes. 
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Table 2.2 Primer nucleotide sequences, Ta (annealing temperature) and 
amplicon length used for PCR experiments. 
2.2.6 Western blot analysis 
Cell lysates were collected after treatments at different time points. 
Samples containing the same amount of protein (40 μg) were separated on 
a 15% SDS (sodium dodecyl sulfate) -polyacrylamide gel electrophoresis, 
transferred to a nitrocellulose membrane (Sigma–Aldrich, Milan, Italy), 
blocked with 5% non-fat milk in TBE (buffer tris-borate-EDTA) and 
probed with specific antibodies. Incubation was performed at 4°C 
overnight with anti-survivin (Ref. sc-17779, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) and anti-β-actin (Ref. A2228, Sigma–Aldrich, 
Milan, Italy) antibodies. Membranes were then washed with blocking 
solution and incubated with secondary antibodies conjugated with 
horseradish peroxidase (Ref. sc-2005, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA). Chemiluminescence detection was performed using 
Western Blotting Luminol Reagent (Ref. sc-2048, Santa Cruz 
Biotechnology, Santa Cruz, USA), according to the manufacturer's 
instructions. Quantification of proteins on SDS-PAGE gels was performed 
using ImageJ densitometry software and signal intensities were normalized 
to those for β-actin. 
2.2.7 Internucleosomal DNA fragmentation  
The Cell Death Detection ELISA (enzyme-linked immunosorbent assay) 
Kit (Ref. 11774452001, Roche, Mannheim, Germany) was used for 
assessing apoptosis in A375 cells treated with MB, according to the 
manufacturer's protocol. Briefly, A375 cells were treated with 100 nM MB 
at different times. After treatment, 10
4
 cells were lysed and centrifuged at 
200 × g for 10 min and the supernatant placed into a streptavidin-coated 
microplate. A mixture of anti-histone-biotin and anti-DNA-POD 
(horseradish peroxidase) was added and incubated at room temperature for 
2 h. After incubation, unbound antibodies were removed from the solution 
and the nucleosomes were quantified by colour development with 
substrate. Optical density was measured at 405 nm with the Infinite
®
 M200 
NanoQuant instrument (Tecan, Salzburg, Austria). 
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2.2.8 Mitochondrial membrane potential (ΔΨm)  
Changes in mitochondrial membrane potential (ΔΨm) during the early 
stages of apoptosis were assayed using the Muse™ MitoPotential assay 
(Ref. MCH 100110, Merck Millipore; Darmstadt, Germany) in A375 cells 
treated with MB alone or in combination with Cis-Pt or DTX. Briefly, cells 
were harvested and the cell pellet was suspended in assay buffer (10
5 
cells/100µl). MitoPotential dye working solution was added and the cell 
suspension incubated at 37 °C for 20 min. After the addition of Muse 
MitoPotential 7-AAD dye (propidium iodide) and incubation for 5 min, 
changes in ΔΨm and in cellular plasma membrane permeabilization were 
assessed using the fluorescence intensities of both the dyes analysed by 
flow cytometry (Muse
TM
 Cell Analyzer, Merck Millipore; Darmstadt, 
Germany). 
2.2.9 Determination of nuclear morphology 
Changes in nuclear morphology were assessed after transfection with MB 
and in lipofectamine-treated cells for 48 and 72 h. Cells were fixed with 
4% paraformaldehyde on 8-well chamber slides. After washing with PBS, 
cells were incubated with DAPI (4',6-diamidino-2-phenylindole) 300 nM 
(Invitrogen Life Technologies, Carlsbad, CA, USA). Life fluorescence 
analysis was realized with Eclipse E600FN Nikon microscope. The 
fluorophore DAPI is a fluorescent label for the blue spectral region 
(excitation and emission wavelengths of 360 and 460 nm, respectively) 
(magnification 40 × WD). 
2-2-10 Statistical analysis 
All experiments were performed in triplicate and results were analyzed by 
GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA). Data were 
shown as mean values ± standard error of the mean (SEM) obtained from 
at least three independent experiments. Statistical analyses were performed 
by Student's t-test or one-way ANOVA followed by the Bonferroni’s 
multiple comparison test. 
2.3 Results 
2.3.1 Survivin mRNA expression in different cell types 
RT-PCR experiments followed by densitometry and quantification of 
electrophoresis bands clearly demonstrated that survivin was differentially 
expressed in human melanoma cells compared to normal cells. 
Specifically, survivin mRNA levels were significantly higher in A375 and 
501 Mel cells than in BSMC (p<0.001), while human melanocytes and 
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monocytes did not express survivin (Fig. 2.2). β-actin was used as 
housekeeping gene because its expression levels did not significantly 
change in all of our experimental conditions. 
 
Figure 2.2 Survivin gene espression in A375, 501 Mel, melanocytes, BSMC, and 
monocytes. Values were expressed as mean ± standard error of the mean (SEM) 
from three separate experiments. ***p<0.001, compared with melanocytes 
(ANOVA followed by the Bonferroni’s multiple comparison test). 
2.3.2 MB specific binding to survivin mRNA  
In vitro bioimaging was used to assess transfection of the MB via 
Lipofectamine into different cell types tested and its target-specific 
structure opening with fluorescence emission. Confocal microscopy of 
living cells clearly demonstrated that MB transfection generated a 
fluorescence signal according to survivin expression levels and time of 
exposure. Specifically, confocal microscopic images of A375 (Fig. 2.3) and 
501 Mel (Fig. 2.4) cells showed high signal intensity in these specific cell 
types indicating that MB could cross the cell membrane, bind to survivin 
mRNA and generate high fluorescence emission. 
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Figure 2.3 Confocal microscopy images of survivin expression in the 
cytoplasm of A375 living cells. Cells were treated with 100 nM MB (red) and 
fluorescence was measured at 1, 2 and 3 h following start of transfection. 
Confocal fluorescent images are shown in the left column, transmission DIC 
(differential interference contras) images in the central column, while the merged 
images are also shown in the right column. The fluorescence images were 
obtained by using excitation and emission wavelengths of 645 and 669 nm, 
respectively and an oil immersion objective (x40, NA=1.3). 
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Figure 2.4 Confocal microscopy images of survivin expression in the 
cytoplasm of 501 Mel living cells. Cells were treated with 100 nM MB (red) and 
fluorescence was measured at 1, 2 and 3 h following start of transfection. 
Confocal fluorescent images are shown in the left column, transmission DIC 
images in the central column, while the merged images are also shown in the right 
column. The fluorescence images were obtained by using excitation and emission 
wavelengths of 645 and 669 nm, respectively and an oil immersion objective 
(x40, NA=1.3). 
Otherwise, the fluorescence signal was significantly lower in the case of 
BSMC cells (Fig. 2.5), while no fluorescence could be detected in human 
melanocytes (Fig. 2.6) and monocytes (Fig. 2.7).  
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Figure 2.5 Confocal microscopy images of survivin expression in the 
cytoplasm of BSMC living cells. Cells were treated with 100 nM MB (red) and 
fluorescence was measured at 1, 2 and 3 h following start of transfection. 
Confocal fluorescent images are shown in the left column, transmission DIC 
images in the central column, while the merged images are also shown in the right 
column. The fluorescence images were obtained by using excitation and emission 
wavelengths of 645 and 669 nm, respectively and an oil immersion objective 
(x40, NA=1.3). 
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Figure 2.6 Confocal microscopy images of survivin expression in the 
cytoplasm of melanocytes living cells. Cells were treated with 100 nM MB (red) 
and fluorescence was measured at 1, 2 and 3 h following start of transfection. 
Confocal fluorescent images are shown in the left column, transmission DIC 
images in the central column, while the merged images are also shown in the right 
column. The fluorescence images were obtained by using excitation and emission 
wavelengths of 645 and 669 nm, respectively and an oil immersion objective 
(x40, NA=1.3). 
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Figure 2.7 Confocal microscopy images of survivin expression in the 
cytoplasm of monocytes living cells. Cells were treated with 100 nM MB (red) 
and fluorescence was measured at 1, 2 and 3 h following start of transfection. 
Confocal fluorescent images are shown in the left column, transmission DIC 
images in the central column, while the merged images are also shown in the right 
column. The fluorescence images were obtained by using excitation and emission 
wavelengths of 645 and 669 nm, respectively and an oil immersion objective 
(x40, NA=1.3). 
Noteworthy, an intense red fluorescent signal was observed (Fig. 2.8) when 
human monocytes were transfected with the fluorescent probe. This 
demonstrated that Lipofectamine was able to transfect both melanoma cells 
and normal cells (i.e., melanocytes and monocytes), and that the MB 
specifically opened with fluorescence emission only in survivin mRNA 
positive cells (i.e., A375 and 501 Mel cells). Specificity of the bases 
forming the MB loop for survivin versus other members of the IAP family 
was confirmed by BLAST analysis. 
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Figure 2.8 Confocal microscopy images of probe in the cytoplasm of 
monocytes living cells. Cells were treated with 100 nM probe (red). Confocal 
fluorescent images are shown in the left column, transmission DIC images in the 
central column, while the merged images are also shown in the right column. The 
fluorescence images were obtained by using excitation and emission wavelengths 
of 645 and 669 nm, respectively and an oil immersion objective (x40, NA=1.3). 
2.3.3 MB downregulation of survivin expression and protein 
synthesis  
We performed real-time PCR experiments to quantitatively assess the 
effect of MB on survivin gene expression in different cell types. Treatment 
with MB for 24 h significantly decreased survivin expression by 79.3±7.6 
% (p<0.01), as compared to cells transfected with control (only 
lipofectamine) in A375 cells (Fig. 2.9).  
 
Figure 2.9 Real-time PCR assessment of survivin gene expression in A375 
cells. Cells were transfected with lipofectamine-MB or treated with lipofectamine 
alone (Ctrl) and analyzed after 24, 48 and 72 hours. Values were expressed as 
mean ± standard of the mean (SEM) from three separate experiments. **p<0.01, 
***p<0.001, (ANOVA followed by the Bonferroni’s multiple comparison test).  
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Prolonged cellular exposure to MB further decreased expression of 
survivin and the maximum effect was reached after 72 h (-94±1.6 %, as 
compared to control). These findings were also confirmed in 501 Mel cells 
in the same experimental conditions (Fig. 2.10). 
 
Figure 2.10 Real-time PCR assessment of survivin gene expression in 501 
Mel cells. Cells were transfected with lipofectamine-MB or treated with 
lipofectamine alone (Ctrl) and analyzed after 24, 48 and 72 hours. Values were 
expressed as mean ± standard of the mean (SEM) from three separate 
experiments. *p<0.05, **p<0.01 (ANOVA followed by the Bonferroni’s multiple 
comparison test).  
Expression levels of survivin protein in A375 cells was assessed by 
western blot and the bands on the blot image were analysed by 
densitometry. In A375 lysates, the survivin antibody mainly labelled a band 
corresponding to an apparent molecular weight of 16.5 KDa. Cell treatment 
with MB time-dependently inhibited survivin protein expression by 
44.3±2.4, 66.1±1.1, and 90.1±1.8 % after 24, 48 and 72 h, respectively, as 
compared to control (Fig. 2.11). 
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Figure 2.11 Detection of survivin protein levels by Western Blot analysis in 
A375 cells. Cells were transfected with lipofectamine-MB or treated with 
lipofectamine alone (Ctrl) and analyzed after 24, 48 and 72 hours. Values were 
expressed as mean ± standard of the mean (SEM) from three separate 
experiments. ***p<0.001, (ANOVA followed by the Bonferroni’s multiple 
comparison test). 
2.3.4 MB induction of apoptosis 
The ability of MB to induce apoptosis in human melanoma cells was 
investigated by evaluating dissipation of mitochondrial membrane potential 
(ΔΨm), internucleosomal DNA fragmentation, and nuclear morphological 
changes. 
Treatment with MB for 48 h induced a significant (p<0.001) variation in 
ΔΨm in about 35% of total cells in A375, suggesting the involvement of 
the intrinsic pathway in the molecular mechanism of MB action. 
Otherwise, control experiments demonstrated the absence of significant 
changes in ΔΨm (Fig. 2.12). A representative dot plots in live, 
depolarized/live, depolarized/dead and dead phase is showed in the upper 
panel in Fig. 2.12.  
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Figure 2.12 Dissipation of the mitochondrial membrane potential (ΔΨm) in 
A375 cells at 48 h. A representative dot plots in live, depolarized/live, 
depolarized/dead and dead phase is showed in the upper panel, whereas the mean 
percentages of the total cell number for each cell status are reported in the lower 
panel. Values were expressed as mean ± standard of the mean (SEM) from three 
separate experiments. ***p<0.001, as compared to control (Student’s t-test). 
MB induced accumulation of histone-complexed DNA fragments in the 
cytoplasmic fraction of A375 cell lysates after 48 and 72 h, while after 24 h 
it did not significantly induce cell death (Fig. 2.13). This is probably due to 
the fact that major DNA fragmentation is a late event in apoptosis. 
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Figure 2.13 Time-dependent fragmentation of internucleosomal DNA in A375 
cells after MB treatment at 100 nM for 24, 48 and 72 h. Values were expressed as 
mean ± standard of the mean (SEM) from three separate experiments. *p<0.05, 
**p<0.01, as compared to 24 h (ANOVA followed by the Bonferroni’s multiple 
comparison test). 
According to this, DAPI staining experiments showed that many A375 and 
501 Mel cells exposed to MB for 48 and 72 h exhibited nuclear 
condensation and chromatin fragmentation, while human melanocytes did 
not (Fig. 2.14). Noteworthy, increased formation of multinucleated cells 
was observed in MB-treated cells, whereas control cells showed normal 
nuclear morphology (data not shown).  
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Figure 2.14 Nuclear morphology revealed by DAPI staining of A375, 501 Mel 
cells and human melanocytes transfected with MB or treated with lipofectamine 
alone (Ctrl) at 48 and 72 h. 
2.3.5 MB enhancement of chemotherapy-induced apoptosis 
To assess the ability of MB to increase the proapoptotic effects induced by 
DTX and CisPt, A375 cells were pre-incubated with MB at 100 nM for 48 
h, followed by DTX at 10 nM or CisPt at 1 µM for 24 h. Apoptosis after 
single agent or combination treatments was analyzed by measuring ΔΨm. 
The combination of MB with DTX or CisPt at low concentrations produced 
an effect greater than that of each drug alone (Fig. 2.15; Fig. 2.16). 
Specifically, the percentage mean values of depolarized A375 cells after 
single DTX and MB treatments were 1.64±0.72 % and 16.34±4.24%, 
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respectively, as compared to control. It is worth mentioning that MB plus 
DTX significantly (p<0.001) increased the percentage of depolarized cells 
up to 33.28±4.59 %, compared to control (Fig. 2.15).  
 
Figure 2.155 Dissipation of the mitochondrial membrane potential (ΔΨm) 
induced by MB and docetaxel (DTX), alone or in combination schedules, in A375 
cells. Cells were pre incubated with MB at 100 nM for 48 h in the presence or 
absence of DTX at 10 nM for 24 h. Values were expressed as mean ± standard of 
the mean (SEM) from three separate experiments. **p<0.01, ***p<0.001, 
compared with MB alone; ##p<0.01, ###p<0.001, compared with DTX alone; 
+++p<0.001, compared with control (Ctrl), (ANOVA followed by the 
Bonferroni’s multiple comparison test).  
The statistical analysis also highlighted a significant (p<0.01) ΔΨm 
increase in combination versus single agent treatments. In a similar 
manner, the percentage of depolarized cells after treatment with single 
CisPt and MB was 10.64±0.92 % and 11.93±2.76 %, respectively, whereas 
it was of 29.98±4.09 % after combination treatment (Fig. 2.16).  
 
Figure 2.16 Dissipation of the mitochondrial membrane potential (ΔΨm) 
induced by MB and cisplatin (CisPt), alone or in combination schedules, in A375 
cells. Cells were preincubated with MB at 100 nM for 48 h in the presence or 
absence of CisPt at 1 µM for 24 h. Values were expressed as mean ± standard of 
the mean (SEM) from three separate experiments. ***p<0.001, compared with 
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MB alone; ###p<0.001, compared with CisPt alone; +++p<0.001, compared with 
control (Ctrl), (ANOVA followed by the Bonferroni’s multiple comparison test).  
2.4 Discussion 
Although depletion of survivin by siRNA has been previously reported to 
increase the sensitivity of cancer cells to chemotherapy in vivo (Li et al., 
2013; Ryan et al., 2009), siRNA-based therapeutics targeting survivin per 
se does not have the potential to detect cancer cells. Our findings provide 
evidence of a novel potential strategy for both cancer diagnosis and 
treatment. Specifically, we deeply characterized in vitro a MB that 
conjugates the ability of imaging of survivin with the pharmacological 
silencing activity in human melanoma cells (Fig. 2.17).  
 
Figure 2.17 Overview of theranostic properties of anti-survivin moleular 
beacon. 
The ability of the MB-lipofectamine system to cross the cell membrane and 
to penetrate into the cytoplasm of A375 and 501 Mel cells was clearly 
demonstrated in the current study by confocal microscopy. Transfection of 
MB into human melanoma cells generated high signal intensity from the 
cytoplasm, while no signal was detected in the extracellular environment or 
in survivin-negative cells (i.e., human melanocytes and monocytes). These 
findings demonstrate the diagnostic capability of the MB that may have 
great potential to translate into clinical applications. In this regards, a 
tumor-specific accumulation in the in vivo setting could be reached via 
nanoparticle-delivered transfection, therefore permitting enhanced 
permeability and retention effect in cancer tissues (Sinha et al., 2006). 
It is widely recognized that survivin expression in melanoma is inversely 
correlated with patient survival (Cheung et al., 2013). Furthermore, high 
survivin expression is associated with resistance to chemotherapeutic 
agents (Groner et al., 2014) and survivin-overexpressing melanoma cells 
have been reported to have a potential role in lung metastasis (McKenzie et 
al., 2010; McKenzie et al., 2013). Therefore, the development of targeted 
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contrast agents (such as fluorescent probes) coupled with optical imaging 
techniques could allow to characterize tumor progression in vivo with great 
sensitivity and selectivity.  
The current study demonstrated the therapeutic potential of the tested MB. 
This MB was already described in literature (Nitin et al., 2004) for the 
detection and quantification of survivin mRNA. However, no evidence was 
provided on its silencing activity in pancreatic cancer cells (Nitin et al., 
2004; Santangelo et al., 2004), whereas other works showed that a partially 
homologous MB did not induce any variation in survivin expression in 
human breast cancer cells (Peng  et al., 2005). 
Concerning the molecular beacon tested in this work, we found that 
treatment with MB markedly decreased survivin mRNA and protein 
expression associated with activation of apoptosis and vitality reduction. In 
line with evidence highlighting the central role of mitochondrial survivin in 
the apoptotic machinery (Dohi et al., 2004), we demonstrated that MB, at 
nanomolar concentrations, induced a significant loss of mitochondrial 
transmembrane potential in A375 cells. Furthermore, the increased 
formation of multinucleated cells observed in the current study after 
transfection with MB is also consistent with the critical role of survivin in 
the regulation of cytokinesis (Vong  et al., 2005; Szafer-Glusman  et al., 
2011). Indeed, survivin is a component of the chromosomal passenger 
complex, which plays a role in chromosome condensation, interaction 
between kinetochores and microtubules at metaphase and midzone 
microtubule organization at anaphase (Szafer-Glusman  et al., 2011). 
Concerning the mechanism of action, MB is a stem-loop hairpin-structured 
oligonucleotide that works as an antisense oligonucleotide. In agreement 
with this notion, selective inhibition of survivin expression by the antisense 
oligonucleotide LY2181308 induced apoptosis, cell cycle arrest in the G2-
M phase, and multinucleated cells (Carrasco et al., 2011). 
Another interesting point that needs to be discussed regards the role of 
survivin in chemoresistance (Pennati et al., 2008). For example, it has been 
reported that both docetaxel and cisplatin induced accumulation of survivin 
in different types of tumors including melanoma (Yamanaka et al., 2011; 
Li et al., 2006), lung (Yang  et al., 2008), breast (Kaneko et al., 2013), and 
gastric (Zheng et al., 2012; Ikeguchi  et al., 2002) cancer. We have found 
that in vitro combination treatment of MB and docetaxel or cisplatin 
induced a greater rate of apoptosis than the sum of the single-treatment 
rates in A375 cells, suggesting that targeting survivin has the potential to 
increase the sensitivity of cancer cells to chemotherapeutics. The effect 
induced by combination schedules appears to be additive because it is 
approximately the sum of the percentage obtained from single treatments, 
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both in terms of depolarized cells (i.e., cells committed to die) and dead 
cells. Moreover, it is also possible that survivin silencing may restore 
sensitivity to targeted therapy. In line with this notion, it has been recently 
demonstrated that blood survivin mRNA positivity was strongly related to 
a poor treatment outcome of EGFR-tyrosine kinase inhibitors in non-small 
cell lung cancer patients (Shi et al., 2014). 
Although general transfection techniques (including those employing 
liposomes or dendrimers) might result in false positive signals, we 
demonstrated that cellular lipofection of tested MB was specific with no 
false positive results. Indeed, a bright red fluorescent signal was observed 
when cells that did not express survivin (i.e., monocytes) were transfected 
with the linear probe (the same fluorescent antisense oligonucleotide of 
MB lacking the quencher molecule), while no signal was detected after MB 
transfection.  
Taken together, our findings provide evidence of a novel potential 
anticancer strategy for the simultaneous imaging and targeted therapy in 
human cutaneous melanoma. The ability to image specific RNAs in vivo 
may offer new opportunities in terms of development of clinical diagnostic 
procedure for the early detection of cancer, pharmacological monitoring of 
silencing effect, and follow-up after surgery or chemotherapy treatment. 
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Chapter 3 
Experimental Section: AM251 
induces apoptosis and G2/M cell 
cycle arrest in A375 human 
melanoma cells 
3.1 Introduction 
AM251 (N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-
methyl-1H-pyrazole-3-carboxamide) (Fig.3.1) is prevalently used as 
cannabinoid 1 receptor CB1R antagonist/inverse agonist but several lines 
of evidence demonstrated that the pharmacological profile of the 
diarylpyrazole derivative is also characterized by CB-independent 
biological actions (Fogli et al., 2006; Patil et al., 2011; Fiori et al., 2011; 
Raffa and Ward, 2012; Seely et al., 2012; Baur et al., 2012; Krzysik-
Walker et al., 2013).  
AM251 is also recognized as agonist/partial agonist of GPR55 receptor 
(Kapur et al., 2009; Sharir and Abood, 2010; Anavi-Goffer et al., 2012) 
however the pharmacology of GPR55 is not completely clear but rather 
sometimes controversial (Ross, 2009; Sharir and Abood, 2010; Anavi-
Goffer et al., 2011) since GPR55 (G protein-coupled receptor 55) ligands 
are lipid molecules able to bind different targets as occurs for cannabinoid 
compounds (Pertwee, 2010).  
Noteworthy, a remarkable anticancer activity of AM251 has been 
documented in pancreatic (Fogli et al., 2006; Fiori et al., 2011) and colon 
cancer cells (Fiori et al., 2011).  
 
Figure 3.1 Molecular structure of AM251. 
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The aim of the present study was to characterize the anti-melanoma activity 
of AM251 against the BRAF V600E mutant cell line, A375, in terms of 
proapototic activity and mechanism of action.  
3.2 Materials and Methods 
3.2.1 Cell cultures 
The human melanoma A375 cell line (American Type Culture Collection, 
Rockville, MD, USA) was cultured at 37°C in a humidified atmosphere 
containing 5% CO2 in DMEM supplemented with l-glutamine (2 mM), 
10% FBS and 1% penicillin/streptomycin (Sigma-Aldrich, Milan, Italy). 
Adult human dermal fibroblasts (HDFa; Ref. C-013-5C, Gibco, Life 
Technologies, CA, USA) were cultured in an optimized medium containing 
10% FBS and 1% (w/v) penicillin/streptomycin, as recommended by the 
manufacturer.  
3.2.2 Drugs 
AM251 (selective CB1 receptor antagonist/inverse agonist and GPR55 
agonist), CID16020046 (selective GPR55 antagonist) and forskolin 
(adenylyl cyclase activator) were obtained from Tocris Bioscience 
(Northpoint, UK). Cisplatin (CisPt), L-α-lysophosphatidylinositol (LPI), 
celecoxib, rofecoxib and indomethacin were purchased from Sigma–
Aldrich, Milan, Italy. Compounds were dissolved in their specific solvents 
(DMSO for AM251, CID16020046, LPI and rofecoxib, water for Cis-Pt, 
and ethanol for others) and further diluted in sterile culture medium 
immediately before their use. DMSO did never exceed 0.33% v/v in the 
culture medium. 
3.2.3 Cell viability assay  
Cell viability was measured using a method based on the cleavage of the 4-
(3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolium)-1,3-benzene 
disulfonate (WST-1) to formazan by mitochondrial dehydrogenase activity 
following manufacturer's instructions (Cell proliferation reagent WST-1; 
Roche, Mannheim, Germany). Briefly, cells (5×10
4
/well) were seeded in 
96-well plate in 10% FBS medium; after 24 h, the complete medium was 
replaced with compound-containing 1% FBS medium. Each compound 
was dissolved in its specific solvent and then diluted in medium up to the 
concentrations to be tested. Freshly stock solutions were prepared. AM251 
was tested in a concentration range of 0.1–50 µM and its effects evaluated 
in the presence or absence of different antagonists added 2 h before. After 
drug treatment, WST-1 was added and, after 1 h, the absorbance was 
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measured at 450 nm using Infinite® M200 NanoQuant instrument (Tecan, 
Salzburg, Austria). Optical density values from vehicle-treated cells were 
considered as 100% cell viability. 
3.2.4 Transfection  
Cells were transfected with GPR55 siRNA (Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA, USA, sc-75183) according to the manufacturer’s 
instructions. Briefly, cells were transfected with 100 nM siRNA using 
Lipofectamine 2000 (Ref. 11668-027, Invitrogen Life Technologies, 
Carlsbad, CA, USA) which has been reported to yield high transfection 
efficiency (≈70%) in A375 cells (Zhou et al., 2013). A scrambled non-
specific siRNA fluorescent conjugate (Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA, sc-36869) was used as control and for preliminary 
confirmation of transfection efficiency through microscope analysis.  
3.2.5 RT-PCR and quantitative real-time PCR analyses 
Total RNA from cells was extracted by using the RNeasy
®
 Mini kit, 
following manufacturer’s instructions, and reverse-transcribed by the 
QuantiTect
®
 Reverse Transcription kit (Qiagen, Valencia, CA, USA). RT-
PCRs were performed by the HotStartTaq Master Mix kit (Qiagen, 
Valencia, CA, USA). Primer sequences are listed in Table 3.1.  
Table 3.1 Primer nucleotide sequences, Ta and amplicon length used for 
PCR experiments. 
Thermal cycle conditions were as follows: 95°C for 15 min, 35 cycles of 
denaturation at 95°C for 1 min followed by annealing and extension at 
72°C for 1 and 10 min, respectively. Detection of the RT-PCR products 
was performed by agarose gel electrophoresis and ethidium bromide 
staining. Real-time PCR was performed with SsoFast Eva Green Supermix 
(Ref. 172-5201, Bio-Rad, CA, USA). Samples were amplified using the 
following thermal profile: 95°C for 30 s, 40 cycles of denaturation at 95°C 
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15 s followed by annealing for 30 s and 72°C for 30 s, with a final step at 
65°C for 5 s. β-actin and GAPDH were used as housekeeping genes. 
3.2.6 Determination of nuclear morphology 
Changes in nuclear morphology of A375 cells were assessed after 
treatment with AM251 or its vehicle for 48 h. Cells were fixed with 2% 
paraformaldehyde on 8-well chamber slides. After washing with PBS, cells 
were incubated with DAPI 300 nM (Invitrogen Life Technologies, CA, 
USA ). Fluorescence analysis was realized with Eclipse E600FN Nikon 
microscope using λex 360 nm and λem 460 nm (magnification 40 × WD). 
3.2.7 Fluorescent microscope analysis of [Ca
2+
]i 
Imaging of [Ca
2+
]i was carried out in A375 cells grown on discs of 35 mm 
diameter. Fluo-3 AM (Ref. F-1242, Molecular probe, Life Technologies, 
CA, USA) was added to the culture medium, the cells were incubated for 
30 min at 37°C dark and then washed with medium. After 30 min of de-
esterification, fluorescence analysis was performed with Eclipse E600FN 
Nikon microscope (water dipping objective 40X, λex 490 nm, λem 520 nm) 
during the perfusion with AM251 and 5 µM ionomycin (Calbiochem, 
Merck Millipore, Darmstadt, Germany) as positive control. The relative 
fluorescence ΔF/F0 was used as an indicator of [Ca
2+
]i in regions of 
interest. To determine the [Ca
2+
]i concentrations, Fura-2 AM (Ref. F1201, 
Molecular probe, Life Technologies, CA, USA) was added to the cells 
previously treated with AM251 or vehicle for 48 h, for 30 min at 37°C in 
the dark. After washing with medium and 30 min of de-esterification, 
fluorescence analysis was performed with Eclipse E600FN Nikon 
microscope. Loaded cells were alternatively excited at 340 and 380 nm 
while they were imaged at 510 nm. After background subtraction, ratio 
images were obtained by dividing, pixel by pixel, pairs of digitized images 
at 340 and 380 nm. Fluorescence values were converted into ion 
concentrations, according to Grynkiewicz et al. (1985). 
3.2.8 Cell Cycle 
The distribution of cells in the different cycle phases was performed using 
the Muse™ Cell Analyzer (Merck KGaA, Darmstadt, Germany). Briefly, 
A375 cells were treated with AM251 (5 μM) or its vehicle for 48 h. 
Asynchronous adherent cells were collected and centrifuged at 300 × g for 
5 minutes. The pellet was washed with PBS (phosphate buffered saline) 
and re-suspended in 100 μl of PBS; finally cells were slowly added to 1 ml 
of ice cold 70% ethanol and maintained o/n at –20°C. Then, a cell 
suspension aliquot (containing at least 2 × 10
5
 cells) was centrifuged at 300 
× g for 5 minutes, washed once with PBS and suspended in the fluorescent 
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reagent (Muse™ Cell Cycle reagent). After incubation for 30 minutes at 
room temperature in the dark, measurements of the percentage of cells in 
the different phases were acquired. 
3.2.9 Statistical analysis 
All experiments were performed in triplicate and results were analyzed by 
GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA). Data were 
shown as mean values ± standard error of the mean (SEM) obtained from 
at least three separate experiments. Statistical analyses were performed by 
Student's t-test or one-way ANOVA followed by the Bonferroni’s multiple 
comparison test. 
3.3 Results 
3.3.1 Effect of AM251 on cell viability  
AM251 at 0.1-50 µM for 24-72 h induced a concentration- and time-
dependent cytotoxicity in A375 cells (Fig. 3.2). The IC50 mean value was 
5.52 ± 1.08 µM and 1.79 ± 1.42 µM after 48 and 72 h, respectively, while 
after 24 h the IC50 was not reached. The IC50 of cisplatin (CisPt), the 
anticancer drug used as reference compound, was 4.33 ± 0.04 µM after 48 
h-exposure.  
 
Figure 3.2 Concentration-dependent cell viability decrease to AM251, in 
A375 melanoma cells after 24, 48 and 72 h exposure to a single drug 
administration. Data are the mean ± SEM from three independent experiments. 
Noteworthy, the IC50 was never reached in human dermal fibroblasts-
adult, HDFa treated with AM251 at 0.1-50 µM for 48 and 72 h (Fig. 3.3). 
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Figure 3.3 Concentration-response curves to AM251 in HDFa cells after 48 
and 72h exposure. Data are the mean ± SEM from three independent experiments. 
3.3.2 Effect of AM251 on apoptosis 
The role played by the apoptotic process in the AM251-induced 
cytotoxicity was assessed measuring variation in gene expression of pro-
/anti-apoptotic proteins and morphological changes in the cell nuclei by 
fluorescence microscopy. AM251 at 5 µM for 48 h increased Bax, 
decreased survivin and Bcl2 gene expression (Fig. 3.4), and induced DNA 
fragmentation and chromatin condensation in the cell nuclei (Fig. 3.5), 
compared to untreated cells.  
 
Figure 3.4 Real-time PCR for the three protein involved in apoptosis in A375 
treated with AM251 for 48 h. Values were expressed as mean ± standard of the 
mean (SEM) from three separate experiments. *p<0.05 as compared with control 
(ctrl) (ANOVA followed by the Bonferroni’s multiple comparison test). 
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Figure 3.5 Nuclear morphology revealed by DAPI staining of A375 cells 
treated with AM251 or vehicle at 48 h. 
The role of intracellular calcium in the pro-apoptotic effect induced by 
AM251 was investigated evaluating the effects of both short and long term 
treatment of A375 cells. A375 cells loaded with Fura-2 AM and treated 
with AM251 5 μM or vehicle for 48 h did not differ in their  intracellular 
concentration of free calcium, as shown in Fig. 3.6. 
 
Figure 3.6 [Ca2+]i levels in Fura-2 AM loaded A375 cells after treatment for 
48 h with AM251 or vehicle (CNTR). Mean values ± SEM (n = 160, P = 0.35 
Student t test). 
3.3.3 Effect of AM251 on cell cycle  
The analysis of cell cycle phase distribution of asynchronous cells was 
assessed by flow cytometry. After treatment with AM251 at 5 μM for 48 h 
the proportion of cells in G0/G1, S and G2/M phases of the cell cycle was 
59.2, 14.7 and 20.2%, respectively. The comparison with untreated cells 
revealed a significant increase of cells in the G2/M and S phases and a 
decrease of cells in G1/G0 phase (Fig. 3.7).  
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Figure 3.7 Cell cycle analyses for asynchronized A375 cells treated with 
AM251 or vehicle at 48 h. Representative cell cycle histograms of control and 
treated cells. The data are presented as percentage of cells in the different phases 
(G0/G1, G2 or S) versus total cell number. Data represent the mean ± SEM of 
three different experiments. *P < 0.05, ** P<0.01, *** P<0.001 from Student’s t-
test. 
3.3.4 Effect of AM251 on GPR55 and TRPA1 
The role of GPR55 on the mechanism of AM251 action was evaluated 
using gene silencing. 100 nM specific siRNA incubated for 24 and 48 h 
time-dependently reduced GPR55 mRNA expression by 40.9 and 72.8%, 
respectively, as compared with scrabbled siRNA treated cells (Fig. 3.8).  
 
Figure 3.8 Real-time PCR results for GPR55 expression, referred to the 
housekeeping gene beta-actin, after 24 h and 48h after siRNA treatment compared 
to control siRNA-treated cells. *** P<0.001 from ANOVA and Bonferroni test. 
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No change was induced by siRNA on AM251-induced cytotoxicity (Fig. 
3.9).  
 
Figure 3.9 Concentration-response curve to AM251 in non-treated cells and 
in cells silenced with GPR55 siRNA. 
Treatment with the potent endogenous GPR55 agonist LPI or the selective 
GPR55 antagonist, CID16020046, up to 30 µM for 48h did not 
significantly affect cell viability  
TRPA1 (Transient receptor potential channel A1) is expressed in A375 
cells (Oehler et al., 2012) and could be a possible target for AM251 (Patil 
et al., 2011). After confirming the presence of TRPA1 by RT-PCR analysis 
(Fig. 3.10), the role of TRPA1 in the AM251-induced cytotoxicity was 
investigated recording calcium changes immediately after treatment in Fluo 
3-AM loaded cells. 
 
Figure 3.10 Ethidium-bromide stained agarose gel revealing TRPA1 gene 
espression (74pb band) in A375 cells. 
Cells loaded with Fluo-3 did not exhibit detectable changes of fluorescence 
during treatment with AM251 at concentrations 0.1-10 μM, while they 
responded to ionomycin 5 μM, as shown in Fig. 3.11. 
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Figure 3.11 Absence of changes in Fluo 3-AM fluorescence during treatment 
with AM251 (0.1-10 μM) and increase of signal after calcium loading induced by 
ionomycin 5 μM. The black and red traces indicate the mean pixel values in the 
regions of interest marked by circles. On the pseudocolor scale blue represents 0 
and red 255. 
3.3.5 Role of COX-2 in AM251-induced cytotoxicity  
We previously reported that COX (cyclooxygenase) enzymes are expressed 
in A375 cells (Adinolfi et al., 2013). In the current study, we found that 
treatment of A375 cells with the selective COX-2 (cyclooxygenase-2) 
inhibitor celecoxib at 0.1-100 μM for 48 h induced cytotoxicity with an 
IC50 of 35.64 ± 1.03 (Fig. 3.12). 
 
Figure 3.12 Concentration-response curves to celecoxib, rofecoxib and 
indomethacin in A375 cells after 48h exposure. Data are the mean ± SEM from 
three independent experiments. 
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At variance with this, no effect on cell viability was observed when cells 
were exposed to rofecoxib (selective COX-2 inhibitor) or indomethacin 
(non-selective COX inhibitor) (Fig. 3.12). 
3.4 Discussion  
In the current study, we demonstrated that AM251 exerted a remarkable 
cytotoxic effect against A375 human melanoma cells with potency 
comparable to that observed for cisplatin. AM251, in the concentration 
range tested against melanoma cells, did not significantly affect the 
viability of proliferating human fibroblasts, suggesting that the compound 
may exhibit some selectivity for cancer cells. To explore in more detail the 
underlying mechanism of AM251, we assessed whether genes encoding for 
Bcl-2, Bax and survivin were a target of AM251. Bax and Bcl-2 are two 
members of the Bcl-2 family that regulates, with opposite effects, the 
release of cytochrome c in mitochondria-dependent apoptosis (Elmore, 
2007), whereas survivin is a member of the IAP family, which inhibits 
caspase-9 activation, a typical enzyme involved in the intrinsic apoptotic 
pathway. In our experimental conditions, the pro-/anti-apoptotic balance 
drifted to the pro-apoptotic side after treatment of A375 cells with AM251. 
Specifically, AM251 reduced the expression of anti-apoptotic Bcl-2 and 
survivin proteins and increased transcription levels of pro-apoptotic Bax. 
Furthermore, AM251, at a concentration that approximate the IC50 value 
obtained in cell viability experiments (i.e., 5 μM) induced characteristic 
features of apoptosis, including DNA fragmentation and chromatin 
condensation. Using real-time imaging with the single-wavelength 
intensity-modulating dye Fluo 3, we did not find changes of intracellular 
Ca
2+ 
in A375 cells during treatment with AM251 at 0.1-10 μM.  
Moreover, dual-wavelength ratiometric indicator Fura-2 allowed us to 
measure the [Ca
2+
]i concentrations in cells treated for 48 h with AM251 5 
μM or vehicle, assessing the maintenance of the intracellular calcium 
homeostasis in both experimental conditions. These findings suggest that 
AM251 can induce apoptosis by a specific Ca
2+
-independent mechanism of 
action. Interesting to note, Gogvadze and co-workers demonstrated a Ca
2+
-
independent mechanism of mithocondria release of cytochrome c via the 
pro-apoptotic protein Bax (Gogvadze et al., 2001) and data of the current 
study showed that AM251 significantly increased Bax expression in A375 
cells. Apoptotic cell death is generally linked to alterations in cell cycle 
program. The percentage of G0/G1 phase cells was considerably decreased 
by AM251 and the parallel increase in the proportion of cells in S-phase 
and G2/M-phase, in treated versus untreated cells, suggests a cell cycle 
arrest at this level. In line with this, drug-induced arrest in the G2 or M 
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phases may be followed by apoptotic cell death (DiPaola, 2002) and a pro-
apoptotic G2 arrest has been already described in A375 melanoma cells 
treated with various agents (Wei et al., 2014; Huang et al., 2014; Das et al., 
2012; Huang et al., 2012).  
Several orphan G-protein coupled receptors have been proposed to act as 
endocannabinoid receptors (Brown, 2007; Pertwee et al., 2010). Among 
these, GPR55 has been recognized as the possible “third” cannabinoid 
receptor (Ryberg et al., 2007; Moriconi et al., 2010) with a role in 
tumorigenesis and metastasis (Pineiro et al., 2011; Andradas et al., 2011; 
Paul et al., 2014). Although AM251 has been recognized to act as 
agonist/partial agonist at GPR55 (Kapur et al., 2009; Sharir and Abood, 
2010; Anavi-Goffer et al., 2012), our findings clearly exclude the 
involvement of GPR55 in the mechanism of AM251 action. Indeed, the 
potent endogenous GPR55 agonist, LPI (Yamashita A et al., 2013) did not 
affect A375 cell viability and no difference in AM251 activity was 
observed in GPR55-silenced cells, compared to controls. AM251 has been 
also reported to activate the transient receptor potential A1 (TRPA1) in 
sensory neurons (Patil et al., 2011) and TRPA1 was found to be expressed 
in A375 cells (Oehler et al., 2012), a condition that has also been confirmed 
in the current study. We therefore investigated whether TRPA1 could be a 
possible target involved in the AM251-induced cancer cell death. Our 
findings demonstrated no early rise in [Ca
2+
]i basal levels after treatment of 
A375 cells with AM251. Since TRPA1 is a non-selective Ca
2+
 permeable 
channel, the anticancer effect of AM251 was probably independent of 
TRPA1 channel activation. Furthermore, data showing that ionic currents 
through TRPA1 are unlikely responsible for the anti-tumour effects of 
highly potent TRPA1-activating compounds in A375 cells (Oehler et al., 
2012), suggest that this receptor type does not have a major role in 
determining the phenotype of human melanoma cells. 
Taking into account the high levels of cyclooxygenase (COX)-2 expressed 
in A375 cells (Adinolfi et al., 2013), we tried to understand whether COX-
2 could play a role in AM251 cytotoxicity. While celecoxib induced 
cytotoxicity in A375 cells, with a potency lower than that observed for 
AM251, other selective and non-selective COX-2 inhibitors did not. It is 
interesting to note that COX-2-inhibitory function is not required for 
celecoxib-mediated apoptosis, which seems to be associated to the 
unbalance between pro- e anti-apoptotic proteins, the activation of intrinsic 
apoptotic pathway, and the delayed progression of cells through the G2/M 
phase of the cell cycle (Grösch et al., 2006). Our findings are in line with 
the previously reported celecoxib-AM251 molecular similarity (Fogli et al., 
60 
2006), which may represent the basis for further investigation on the 
molecular mechanism of AM251 (Fig. 3.13). 
 
Figure 3.13 Celecoxib-AM251 molecular similarity (Fogli et al., 2006). 
Overall, the results of the current study suggest that AM251 could be a 
prototypical compound for the development of promising diarylpyrazole 
derivatives in human cutaneous melanoma. 
 
Nomenclature 
501-Mel Metastatic melanoma cell line 
A375   Metastatic melanoma cell line 
AJCC   American Joint Committee on Cancer  
Akt  Protein kinase B (PKB) 
AM251 (N-(Piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-
dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide) 
AMP  Adenosine monophosphate 
AMPK AMP-activated protein kinase  
AP-1  Activator protein 1 
APC   Antigen-presenting cell  
ATP  Adenosine triphosphate 
Bad   Bcl-2-associated death promoter 
Bax               Bcl-2-associated X protein 
Bcl-2  B-cell lymphoma 2  
BSMC  Human Bronchial Smooth Muscle Cells 
CB1R Cannabinoid receptor subtypes 1 
CB2R Cannabinoid receptor subtypes 2  
CD271 Low affinity nerve growth factor receptor 
CD28  Cluster of Differentiation 28 
CDK  Cyclin dependent kinase  
CDK2   Cyclin dependent kinase type 2 
CDK4   Cyclin dependent kinase type 4 
CDK6  Cyclin dependent kinase type 6 
CDKN2A Cyclin-dependent kinase inhibitor 2A 
CisPt  Cisplatin  
CK2  Protein kinase 2 or casein kinase II 
CKII  Casein kinase II or protein kinase 2 
c-KIT  Tyrosine-protein kinase or CD117 
COX             Cyclooxygenase 
COX-2          Cyclooxygenase-2 
CREB  cAMP response element-binding protein 
CSC  Cancer stem cells  
CTLA-4 Cytotoxic T-Lymphocyte Antigen 4 
CTRL  Control 
DAPI  4',6-diamidino-2-phenylindole 
DIC  Differential interference contrast 
DMEM          Dulbecco's modified Eagle's medium 
DMSO Dimethyl sulfoxide 
DTX   Docetaxel 
ECS              Endocannabinoid system  
EGFR  Epidermal growth factor receptor  
ELISA  Enzyme-linked immunosorbent assay 
EMA  European Medicine Agency 
ERK  Extracellular signal-regulated kinases  
ERK1  Extracellular signal-regulated kinase 1 
ERK2  Extracellular signal-regulated kinase 2 
FBS  Fetal bovine serum  
FDA   US Food and Drug Administration 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GDP  Guanosine diphosphate 
GPR55          G protein-coupled receptor 55 
GSK3  Glycogen synthase kinase 3 
GTP  Guanosine -5'triphosphate 
GβL   G protein β-like 
HDFa            Adult Human Dermal Fibroblasts 
HIF1   Hypoxia-inducible factor-1 
HSP90  Heat-shock protein 90  
IAP  Inhibitor of apoptosis 
IGF  Insulin-like growth factor 
IkB   Nuclear factor of kappa light polypeptide gene enhancer in 
B-cells inhibitor 
IKK  Inhibitor of nuclear factor kappa-B kinase 
IL-2  Interleukin-2 
INF-α2b Interferon alpha 2b  
Jak  Janus kinase 
JNK  Jun N-terminal kinases 
LPI  L-α-lysophosphatidylinositol  
MAPK  Mitogen-activated protein kinase 
MB  Molecular beacon oligodeoxyribonucleotides 
MC1R  Melanocortin 1 receptor 
MDM2  Mouse double minute 2 
MIMIC Malignant melanoma-initiating cell  
MITF  Microphthalmia-associated transcription factor 
mTOR  Mammalian target of rapamycin 
mTORC1 Mammalian target of rapamycin complex 1 
mTORC2 Mammalian target of rapamycin complex 2 
NA  Numerical aperture 
NCCN  National Comprehensive Cancer Network 
NF-κB  Nuclear factor kappa-light-chain-enhancer of activated B 
cells 
NIK  NF-kappa-B-inducing kinase 
OS  Overall survival  
p14
ARF
  ARF tumor suppressor 
p16
INK4
 Cyclin-dependent kinase inhibitor 2A 
p21  Cyclin-dependent kinase inhibitor 1 
p27
KIP1
 Cyclin-dependent kinase inhibitor 1B 
p38  Mitogen-activated protein kinases 
p53  Cellular tumor antigen p53 
p65  Transcription factor p65 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PD-1   Programmed death-1 or programmed cell death-1 
PDGF  Platelet-derived growth factor 
PDK1  Phosphoinositide dependent protein kinase-1  
PD-L1  Programmed death-ligand 1 
PD-L2  Programmed death-ligand 2 
PI3K  Phosphatidylinositol-3-kinase  
PIP2  Phosphatidylinositol-4,4-bisphosphate  
PIP3  Phosphatidylinositol-3,4,5-triphosphate  
PKA   Protein kinase A 
PKB  Protein kinase B 
PKC  Protein kinase C 
POD  Horseradish peroxidase 
PTEN  Phosphatase and tensin homolog 
RAPTOR Regulatory-associated protein of mTOR 
Rb  Retinoblastoma  
RICTOR Rapamycin-insensitive companion of mammalian target of 
rapamycin 
RTK  Receptor tyrosine kinase 
RT-PCR Reverse transcriptase polymerase chain reaction 
SCF  Stem cell factor  
SDS  Sodium dodecyl sulfate 
SEM  Standard error of the mean  
siRNA  Small or short interfering RNA  
SLNB  Sentinel lymph node biopsy  
SOS  Son of sevenless 
STAT  Signal transducer and activator of transcription 
Ta  Annealing temperature 
TBE  Buffer tris-borate-EDTA 
TNF   Tumor necrosis factor  
TNFR             Tumor necrosis factor receptor 
TNM    Tumor-Node-Metastasis 
TRAF   Tumor necrosis factor receptor associated factor 
TRPA1  Transient receptor potential channel A1 
VEGF    Vascular endothelial growth factor 
WST-1 4-(3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolium)-    
1,3-benzene disulfonate 
ΔΨm     Mitochondrial membrane potential  
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